Breast Cancer Recurrence DNA Assay In Development; Exagen Targets HCV
This article was originally published in The Pink Sheet Daily
The breast cancer diagnostic developer is planning a pivotal trial of its DNA assay to guide chemotherapy in patients by testing disease recurrence. Exagen’s study aims to validate results of a 308-patient trial.
You may also be interested in...
Zila Medical bypasses lengthy CDER regulatory path, gains 510(k) clearance for ZTC tolonium chloride compound at CDRH. Oral cancer test’s identical compound, OraTest, remains under CDER review.
National Quality Care plans to file an investigational device exemption within the next few months to begin human studies for a wearable artificial kidney device. Nephros, meanwhile, is conducting Phase II trials of a bioartificial kidney.
The firm is preparing to submit an investigational device exemption for a pivotal trial supporting a premarket application for its CoStar cobalt chromium stent. However, a market launch could be hindered by intellectual property issues over use of the drug.